Lazaros C Triarhou
Lazaros C Triarhou
Application of the anti-IgLON5 disease composite score to assess severity, clinical course, and mortality in a French cohort [0.03%]
抗IGLON5疾病复合评分在法国队列中用于评估严重程度、临床过程和死亡率的应用
Antonio Farina,Macarena Villagrán-García,Amna Abichou-Klich et al.
Antonio Farina et al.
Anti-IgLON5 disease presents with diverse symptoms, whose severity can be measured by the anti-IgLON5 disease composite score (ICS). This study applied the ICS to a retrospective anti-IgLON5 disease cohort (n = 52; median age 72 years, 63% ...
Flexible exoskeleton-assisted training enhances lower limb motor function after stroke: a systematic review and meta-analysis [0.03%]
柔性外骨骼辅助训练可提高中风后的下肢运动功能：系统评价和荟萃分析
Jiawei Liu,Kai Liu,Xuanxuan Ge et al.
Jiawei Liu et al.
Background: Recent advances in flexible exoskeleton technology have broadened its application in stroke rehabilitation, particularly for improving motor functions in the affected lower limb. This review examines the impac...
Gray matter structural and functional brain abnormalities in Parkinson's disease: a meta-analysis of VBM and ALFF data [0.03%]
帕金森病的灰质结构和功能异常的Meta分析：基于VBM和ALFF数据的方法
Lu Wang,Xin Xiong,Junqi Liu et al.
Lu Wang et al.
Background: Previous studies based on resting-state functional imaging and voxel-based morphometry (VBM) have revealed structural and functional alterations in several brain regions in patients with Parkinson's disease (P...
Aprosopsia: a novel metamorphopsia variant occurring in Parkinson's disease psychosis [0.03%]
阿普罗普斯卡：帕金森病精神病中新出现的一种变形症变异形式
Anish Bandalore Satheesha Reddy,Sara Pisani,Sajini Kuruppu et al.
Anish Bandalore Satheesha Reddy et al.
Safety and efficacy of chronic weekly rozanolixizumab in generalized myasthenia gravis: the randomized open-label extension MG0004 study [0.03%]
慢性每周rozanolixizumab治疗全身型重症肌无力的安全性和有效性：随机开放标签扩展MG0004研究
Vera Bril,Artur Drużdż,Julian Grosskreutz et al.
Vera Bril et al.
Background: In the Phase 3 MycarinG study (NCT03971422), six once-weekly subcutaneous infusions of rozanolixizumab significantly improved myasthenia gravis (MG)-specific outcomes versus placebo in patients with acetylchol...
Clinical Trial
Journal of neurology. 2025 Mar 19;272(4):275. DOI:10.1007/s00415-025-12958-9 2025
MAPT mutations in amyotrophic lateral sclerosis: clinical, neuropathological and functional insights [0.03%]
肌萎缩性侧索硬化症中的MAPT基因突变：临床、神经病理及功能研究
Sibylle De Bertier,Géraldine Lautrette,Maria-Del-Mar Amador et al.
Sibylle De Bertier et al.
Background: Amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) are part of a well-established disease continuum, underpinned by TDP43-pathology. In contrast, the clinical manifestations of Tau-linked di...
Sophia Vera Frølich,Noémie Receveur,Nanna Scharff Poulsen et al.
Sophia Vera Frølich et al.
Background: Spinal muscular atrophy (SMA) is a motor neuron disease with loss of musculature, which is replaced by fat. Previous magnetic resonance imaging (MRI) studies have focused on imaging muscles either in lower or ...
Long-term CSF responses in adult patients with spinal muscular atrophy type 2 or 3 on treatment with nusinersen [0.03%]
使用nusinersen治疗的2型或3型脊髓性肌萎缩成人患者的长期脑脊液反应
Gina Cebulla,Ling Hai,Uwe Warnken et al.
Gina Cebulla et al.
Background: 5q-associated spinal muscular atrophy (SMA) is a monogenic disease causing progressive alpha motor neuron degeneration, muscle atrophy, and weakness. Intrathecal therapy with the antisense oligonucleotide nusi...
A decision aid is not the quick fix for improving shared decision-making in advanced Parkinson's disease: results of a mixed methods feasibility study [0.03%]
决策辅助工具并不能快速改善晚期帕金森病的共享决策：混合方法可行性的研究结果
Frouke A P Nijhuis,Bas Schippers,Bastiaan R Bloem et al.
Frouke A P Nijhuis et al.
Background: Choosing a device-assisted treatment for persons with Parkinson's disease (PwPD) is a complex decision. We developed a shared decision-making (SDM) intervention to facilitate this decision. In this study, we e...
Multicenter Study
Journal of neurology. 2025 Mar 13;272(4):269. DOI:10.1007/s00415-025-12972-x 2025